Effects of preoperative enoxaparin versus unfractionated heparin on bleeding indices in patients undergoing coronary artery bypass grafting.

[1]  B. Horne,et al.  Preoperative Use of Enoxaparin Compared With Unfractionated Heparin Increases the Incidence of Re-Exploration for Postoperative Bleeding After Open-Heart Surgery in Patients Who Present With an Acute Coronary Syndrome: Clinical Investigation and Reports , 2002, Circulation.

[2]  B. Boutouyrie,et al.  The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers , 2002, Clinical pharmacology and therapeutics.

[3]  R. Hongo,et al.  The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. , 2002, Journal of the American College of Cardiology.

[4]  R. Hongo,et al.  The effect of clopidogrel incombination with aspirin whengiven before coronary artery bypass grafting , 2002 .

[5]  C. Grines,et al.  Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. , 2001, The Journal of invasive cardiology.

[6]  G. Montalescot,et al.  Percutaneous Coronary Intervention After Subcutaneous Enoxaparin Pretreatment in Patients With Unstable Angina Pectoris , 2001, Circulation.

[7]  S. Clark,et al.  Effect of low molecular weight heparin (fragmin) on bleeding after cardiac surgery. , 2000, The Annals of thoracic surgery.

[8]  E. Antman,et al.  Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. , 1999, Circulation.

[9]  E. Antman,et al.  Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. , 1999, Circulation.

[10]  G. Despotis,et al.  Preoperative use of enoxaparin and tirofiban: possible association with increased bleeding postbypass. , 1999, Anesthesiology.

[11]  B. Griffith,et al.  Abciximab and excessive bleeding in patients undergoing emergency cardiac operations. , 1998, The Annals of thoracic surgery.

[12]  P Théroux,et al.  Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. , 1998, Circulation.

[13]  R. Califf,et al.  A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. , 1997 .

[14]  W. Klein,et al.  Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC) , 1997, Circulation.

[15]  E. Gurfinkel,et al.  Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. , 1995, Journal of the American College of Cardiology.

[16]  A. Telford,et al.  TRIAL OF HEPARIN VERSUS ATENOLOL IN PREVENTION OF MYOCARDIAL INFARCTION IN INTERMEDIATE CORONARY SYNDROME , 1981, The Lancet.

[17]  T C Chalmers,et al.  Evidence favoring the use of anticoagulants in the hospital phase of acute myocardial infarction. , 1977, The New England journal of medicine.

[18]  W. Hoyt,et al.  Letter: Suprastriate hemianopia. , 1974, Lancet.

[19]  A Drapkin,et al.  Anticoagulant therapy after acute myocardial infarction. Relation of therapeutic benefit to patient's age, sex, and severity of infarction. , 1972, JAMA.

[20]  ACC/AHA guidelines for the management of patients with unstable angina and non-ST segment elevation myocardial infarction: executive summary and recommendations. , 2000, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[21]  M. Keltai,et al.  Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome). , 1999, European heart journal.